|Home | About | Journals | Submit | Contact Us | Français|
The prevalence of obesity-related diabetes is increasing worldwide. Here we report the identification of a pentapeptide, GLP-1(32-36)amide (LVKGRamide), derived from the glucoincretin hormone GLP-1, that increases basal energy expenditure and curtails the development of obesity, insulin resistance, diabetes, and hepatic steatosis in diet-induced obese mice. The pentapeptide inhibited weight gain, reduced fat mass without change in energy intake, and increased basal energy expenditure independent of physical activity. Analyses of tissues from peptide-treated mice reveal increased expression of UCP-1 and UCP-3 in brown adipose tissue and increased UCP-3 and inhibition of acetyl-CoA carboxylase in skeletal muscle, findings consistent with increased fatty acid oxidation and thermogenesis. In palmitate-treated C2C12 skeletal myotubes, GLP-1(32-36)amide activated AMPK and inhibited acetyl-CoA carboxylase, suggesting activation of fat metabolism in response to energy depletion. By mass spectroscopy, the pentapeptide is rapidly formed from GLP-1(9-36)amide, the major form of GLP-1 in the circulation of mice. These findings suggest that the reported insulin-like actions of GLP-1 receptor agonists that occur independently of the GLP-1 receptor might be mediated by the pentapeptide, and the previously reported nonapeptide (FIAWLVKGRamide). We propose that by increasing basal energy expenditure, GLP-1(32-36)amide might be a useful treatment for human obesity and associated metabolic disorders.
The prevalence of obesity and associated diabetes and metabolic disorders has increased dramatically over the past 20 years. Obesity-related metabolic disorders are manifested as insulin resistance, diabetes, hypertension, hyperlipidemia, hepatic steatosis, and accelerated atherosclerosis. Although the pathophysiology underlying these disorders remains unknown, insulin resistance appears to be a major contributor (1–4). Currently, effective treatments for obesity are not available. Here we report that a pentapeptide, GLP-1(32-36)amide (LVKGRamide), derived from the C terminus of the glucoincretin hormone GLP-1, increases basal energy expenditure, inhibits weight gain, reduces fat mass, and reduces the development of insulin resistance and hepatic steatosis when administered to diet-induced obese (DIO) mice.
GLP-1 receptor agonists are in use for the treatment of type 2 diabetes based on their stimulation of insulin secretion and a lowering of glucagon levels (5,6). The full-length receptor agonist GLP-1(7-36)amide is rapidly inactivated in the circulation via cleavages by the endopeptidase dipeptidyl peptidase-4 (Dpp4) and a neutral endopeptidase (NEP 24.11) known as neprilysin (7,8). The cleavage of GLP-1(7-36)amide by Dpp4 gives rise to GLP-1(9-36)amide devoid of insulin-releasing activities, and NEP 24.11 cleaves GLP-1 into several small peptides (9). Earlier we proposed that cleavages of GLP-1 by the endopeptidase neprilysin generate a pentapeptide and a nonapeptide, GLP-1(28-36)amide (FIAWLVKGRamide), with insulin-like actions on insulin-responsive target tissues (10). GLP-1(9-36)amide, the product of cleavage of GLP-1 by Dpp4, exerts insulin-like and antioxidant actions on the heart (11–14) and vasculature (15) and suppresses glucose production both in isolated mouse hepatocytes (16) and in obese, insulin-resistant human subjects without effect on plasma insulin levels (17). The administration of GLP-1(9-36)amide or the nonapeptide to obese mice increases energy expenditure, curtails weight gain, and inhibits the development of insulin resistance, diabetes, and hepatic steatosis (18,19). In obese mice, the nonapeptide promotes glucose disposal and β-cell regeneration in streptozotocin-induced diabetic mice (20), protects β-cells against glucolipotoxic stress (21), and suppresses hepatic glucose production in obese mice (22). The nonapeptide appears to enter isolated insulin-resistant mouse hepatocytes in vitro, targets to mitochondria, suppresses glucose production and reactive oxygen species, and restores cellular ATP levels that are depleted by oxidative stress (22,23). The actions of the peptides appear to occur preferentially in obese, insulin-resistant compared with lean, insulin-sensitive human subjects (17) or mice (19) and occur by mechanisms independent of the GLP-1 receptor (10,24). Because both peptides are major end products of the proteolysis of GLP-1 by neprilysin (9) in addition to the nonapeptide, we investigated the actions of the pentapeptide (10) in DIO mice. We find that the pentapeptide increases basal energy expenditure, curtails weight gain, and inhibits the development of insulin resistance, diabetes, and hepatic steatosis independently of energy intake or physical activity. The expression of the uncoupling proteins UCP-1 and UCP-3 is increased in the brown adipose tissue (BAT), as is UCP-3 in skeletal muscle of obese mice in response to GLP-1(32-36)amide, findings consistent with an increase in basal energy expenditure. In addition, the activity of acetyl-CoA carboxylase is inhibited in the skeletal muscle of the peptide-treated mice, indicative of an increase in fatty acid oxidation. In C2C12 skeletal myotubes in vitro, GLP-1(32-36)amide activates AMPK and inhibits acetyl-CoA carboxylase (ACC), further supporting increased fatty acid oxidation. These findings of novel energy-modulatory actions of the pentapeptide in obese mice suggest the possibility that it might be an effective treatment for obesity-related diabetes.
GLP-1(LVKGRamide) was synthesized by solid phase methods. The peptide was purified to a single component on HPLC, and by mass spectroscopy the product molecular weight was 571.38.
C57BL/6J male mice of 6–9 weeks of age were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were housed four per cage under a light/dark cycle of 12 h with free access to food and water, except when noted. Mice were fed a regular laboratory chow (10 kcal % fat, D12450B; Research Diets) or a high-fat diet (HFD) (60 kcal % fat, D12492; Research Diets) throughout the studies. All procedures were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee.
Mice 21 weeks of age on a regular laboratory chow or HFD for 15 weeks were given intraperitoneal injections of 500 μg of GLP-1(9-36)amide. Blood samples were collected from the tail vein at 0, 5, and 15 min and by cardiac puncture at 30 min after the administration of GLP-1(9-36)amide. Plasmas were analyzed for the formation of GLP-1(32-36)amide. Peptide extraction was performed by acetonitrile precipitation (25,26) and detection by liquid chromatography–mass spectroscopy (LC-MS) with an Agilent 1200 HPLC and Applied Biosystems Qtrap 4000 mass spectrometer with a Turbo Spray ion source.
At 6–10 weeks of age, mice were placed on an HFD for 7–22 weeks. At 13–28 weeks of age, mice were randomized by average body weight (vehicle group, 38.1 g; peptide treated group, 37.3 g) and were implanted with mini-osmopumps (1004; ALZET) to infuse vehicle (0.154 mol/L NaCl/0.2% human serum albumin) or GLP-1(32-36)amide (50–70 nmol/kg body weight/day) over 12–19 weeks (19). During the infusion studies, body weights and food intake were monitored weekly and twice weekly, respectively. Fat and lean body mass were assessed on week 15 of the pentapeptide infusions using a whole-body dual X-ray scanner (Lunar Piximus; GE Medical Systems, Wauwatosa, WI).
Tissue staining (hematoxylin-eosin) of livers and levels of triglycerides in liver extracts and plasmas (28) of mice at the end of the 15-week infusion and 32 weeks on high fat were determined as described previously (18).
Mice at 30 weeks on HFD and 12-week infusions with vehicle or GLP-1(32-36)amide were single caged for 5 days before placing them into individual metabolic chambers for 2 days for acclimatization, with free access to food and water. Oxygen consumption was determined by indirect calorimetry (TSE Systems). Oxygen consumption was measured at 5-min intervals for a total of 120 h. The results presented correspond to the last 6 h of the light cycle and 12 h of the dark cycle. Locomotor activity was determined by counting infrared light beam breaks (InfraMot Phenomaster/LabMaster cage system). Results are presented for the last 6 h of the light cycle and complete dark cycle and the average activity during both dark and light phases.
Plasma glucose and insulin levels were obtained in fasted (16 h) mice fed an HFD for 29 weeks and treated with pentapeptide or vehicle for 12 weeks. Glucose tolerance tests were performed on mice at 24 weeks on HFD and 16-week infusions with vehicle or GLP-1(32-36)amide and were fasted overnight (16 h). Glucose (2 g/kg lean mass) was administrated by intraperitoneal injection. Blood samples were drawn from the tail vein at 0, 10, 30, 60, 120, and 140 min after glucose administration. Insulin tolerance tests were performed on mice at 38 weeks on HFD and 19-week infusions with either vehicle or GLP-1(32-36)amide. Mice were fasted for 4 h and given 0.75 units/kg lean mass insulin by intraperitoneal injection. Blood glucose was monitored at 0, 15, 30, 45, and 60 min after insulin injection. Blood draws were obtained by tail nick, and plasma glucose was measured using a glucometer OneTouch UltraMini glucose meter (LifeScan, Johnson & Johnson Company, Philadelphia, PA). Fasting insulin levels were determined using the rat/mouse ELISA kit (Crystal Chem, Downers, IL). Area under the curve (AUC) was determined by standard methods.
C2C12 skeletal muscle cells were obtained from ATCC (Manassas, VA) and cultured in growing media (DMEM media: 25 mmol/L glucose, 10% FBS, and 1% penicillin and streptomycin) until differentiation when cells were cultured in differentiation media (DMEM: 25 mmol/L glucose, 2% horse serum, and 1% penicillin and streptomycin). Experiments were carried out at day 5 of differentiation. C2C12 myotubes were fasted for 6 h (no serum added) before incubation with GLP-1(32-36)amide (100 pmol/L) and/or 0.2 mmol/L palmitate:0.034 mmol/L BSA (5:1) for 16 h in fasting media.
Cells lysates of C2C12 myotubes (15 μg), gastrocnemius muscle homogenates (15 μg), and BAT homogenates (10 μg) from in vivo mouse studies were resolved by SDS-PAGE, and proteins were analyzed by the Western immunoblot procedure as previously described (16) (see Fig. 5 legend).
C2C12 myoblasts were seeded in 12-well fluorescence plates grown until confluence and differentiated to myotubes for 5 days. Reactive oxygen species (ROS) levels were determined in palmitate-treated myotubes as previously described (23) (see Fig. 6 legend).
Mouse tissues were removed and immediately submerged in cold RNAlater (QIAGEN, Valencia, CA) or frozen in liquid nitrogen. Total RNA was isolated and analyzed by quantitative PCR (qPCR) (CFX 384; Bio-Rad, Richmond, CA) as previously described (16). The primers used for qPCR are available upon request.
Data are presented as mean ± SEM. Statistical analyses were performed using Student t test. P values <0.05 were considered to be statistically significant.
GLP-1(7-36)amide is rapidly cleaved in vivo (1–2 min) by Dpp4 to GLP-1(9-36)amide, a peptide devoid of significant insulinotropic activities (8) and is the major form of GLP-1 in the circulation. GLP-1(9-36)amide has insulin-like actions on heart, vasculature, and liver (10,16–19,24,28). Additional cleavages of GLP-1 occur by the endopeptidase NEP 24.11 in vitro, resulting in the formation of the nona- and pentapeptides GLP-1(28-36)amide and GLP-1(32-36)amide as major products, respectively (9) (Fig. 1A). To examine the formation of the pentapeptide by cleavage from GLP-1(9-36)amide in lean and obese mice, we administered GLP-1(9-36)amide by intraperitoneal injection and collected blood samples at 0, 5, 15, and 30 min for analyses of the levels of the peptides by semiquantitative LC-MS. GLP-1(9-36)amide appears in plasma within 5 min and was undetectable by 30 min, respectively, after the injection of GLP-1(9-36)amide (Fig. 1B). At 5 min, the plasma concentrations of GLP-1(9-36)amide, GLP-1(28-36)amide, and GLP-1(32-36)amide in lean mice were 3.3 μmol/L, 4 μmol/L (data not shown), and 80 nmol/L, respectively (Fig. 1B). The plasma levels of the nona- and pentapeptides are 5- to 10-fold lower in the obese compared with the lean mice.
At 6–10 weeks of age, mice were placed on an HFD for 17–18 weeks before beginning the continuous infusions of vehicle or GLP-1(32-36)amide for 12–16 weeks. The infusion of GLP-1(32-36)amide for 12 weeks attenuated the development of DIO (Fig. 2A). Mice receiving GLP-1(32-36)amide for 10 weeks gained less weight compared with vehicle control, at which time the peptide-treated mice began to lose weight (Fig. 2B). The average weekly change in body weight gain of mice infused with the pentapeptide was 50% less than that of mice receiving control vehicle over the 10-week infusion period (Fig. 2C). Caloric intakes in peptide- and vehicle-treated mice were similar (Fig. 2D). The FE indicated that 80% less of the caloric intake went into body weight in mice treated with the pentapeptide compared with vehicle (vehicle control, 0.016 ± 0.0018; pentapeptide treated, 0.003 ± 0.00075; P = 0.06).
Measurement of body fat and lean mass by DEXA between vehicle and GLP-1(32-36)amide mice treated for 16 weeks showed a 40% reduction in fat mass in the GLP-1(32-36)amide–infused mice compared with vehicle and no significant changes in lean mass (Fig. 2E and F). GLP-1(32-36)amide decreases liver fat accumulation when compared with vehicle, as shown in the hematoxylin-eosin staining liver tissue sections (Fig. 2G). The triglyceride contents in livers of mice receiving GLP-1(32-36)amide decreased by 60% when compared with vehicle and were similar to that of mice fed a regular chow diet (21.13 ± 5.6 mg/mL in livers of mice infused with GLP-1(32-36)amide compared with 21.6 ± 7 mg/mL protein in mice fed regular chow) (Fig. 2H). Moreover, the pentapeptide reduced both plasma glycerol levels (0.12 ± 0.025 mg/mL compared with 0.25 ± 0.04 mg/mL vehicle control; P < 0.02) and triglyceride levels (0.33 ± 0.06 mg/mL compared with 0.65 ± 0.06 mg/mL vehicle control; P < 8E-04) (Table 1).
Before beginning the treatment of DIO mice, the fasting glucose and insulin levels were similar among the two pretreatment groups of mice: vehicle mice (glucose, 4.8 ± 1.08 mmol/L; insulin, 209.2 ± 89.17 pmol/L) and peptide-treated mice (glucose, 4.3 ± 0.2 mmol/L; insulin, 116.7 ± 38 pmol/L). The infusions of GLP-1(32-36)amide for 12 weeks attenuated the progression of fasting hyperglycemia and hyperinsulinemia (Table 1).
To further determine the actions of GLP-1(32-36)amide on glucose homeostasis in DIO mice, intraperitoneal glucose and insulin tolerance tests were performed in mice receiving continuous infusions of the pentapeptide for 10 weeks. Mice fed an HFD for 24 weeks exhibited impaired glucose tolerance after the glucose challenge. The infusion of GLP-1(32-36)amide for 16 weeks resulted in an improvement in the glycemic excursion over the 140 min of the glucose tolerance test (Fig. 3A, left panel). Fasting plasma glucose and insulin levels at the beginning of the glucose tolerance challenge were reduced in GLP-1(32-36)amide–infused mice (glucose: 169.16 ± 7.5 mg/dL compared with 221.5 ± 8.6 mg/dL vehicle control [P < 4.3E-04], and insulin: 409.7 ± 65.2 pg/mL compared with 654.8 ± 129 pg/mL vehicle control). Mice receiving pentapeptide showed a lower AUC, indicating improved glycemic control (Fig. 3, upper right panel). Plasma insulin concentrations 10 min after glucose administration were higher in mice receiving GLP-1(32-36)amide (Fig. 3, lower right panel), a finding consistent with an increase in the insulin-to-glucose ratio in GLP-1(32-36)amide–infused mice (pentapeptide: 4.7 ± 1.78 compared with vehicle 1.5 ± 0.52; P < 0.048). Likewise, mice fed an HFD for 38 weeks and receiving GLP-1(32-36)amide for 19 weeks showed a more pronounced glucose-lowering response compared with that of vehicle-treated mice when challenged with an insulin tolerance test. These results suggest that mice infused with the pentapeptide are more insulin responsive when compared with the glucose response of vehicle-treated mice (Fig. 3B, right panel). The AUC glucose following insulin administration was lower in mice receiving GLP-1(32-36)amide than in vehicle-treated mice (Fig. 3B, left panel). Thus, GLP-1(32-36)amide administration protects the obese mice from the development of insulin resistance.
To determine whether the attenuation of weight gain by GLP-1(32-36)amide was associated with changes in energy homeostasis, indirect calorimetry was performed in mice fed an HFD for 30 weeks and at the end of 12 weeks of treatment with GLP-1(32-36)amide. GLP-1(32-36)amide increased both total body and lean body resting oxygen consumption during the light and dark cycles (Fig. 4A and B, left panels). Total body oxygen consumption rates increased by 22 and 33% over the light and dark phases, respectively (Fig. 4A, right panel). No differences were observed between control and pentapeptide-treated mice in either energy intake (data not shown) or physical activity (Fig. 4C). Thus, these findings indicate that the regulatory effects of GLP-1(32-36)amide on energy homeostasis are associated with an increase in basal energy expenditure.
Because of the finding of an increase in basal energy expenditure in the pentapeptide-treated mice, we examined BAT, a known thermogenic tissue (29,30), for effects of GLP-1(32-36)amide on the expression of uncoupling proteins. The protein expression of both UCP-1 and UCP-3 in BAT was significantly increased in mice infused with GLP-1(32-36)amide for 15 weeks and on an HFD for 32 weeks when compared with obese vehicle control mice (Fig. 5A and B). Likewise, mRNA expression for both UCP-1 and UCP-3 was increased by ~1.5–2-fold in mice receiving pentapeptide (Fig. 5C). The expression of the transcriptional coactivator PGC-1α, known to modulate the expression of UCP-1, oxidative metabolism, and thermogenesis in BAT (31), was increased in BAT of mice receiving the pentapeptide. Likewise, the expression of PPARα, known to have important actions in the modulation of fatty acid oxidation (32), was increased (Fig. 5C). Cytochrome C expression was also increased, although the increase did not reach statistical significance (Fig. 5C). Because skeletal muscle accounts for 20% of overall energy metabolism (33), we explored the role of skeletal muscle on energy homeostasis in obese mice treated with the pentapeptide. The ratio of phosphorylated to total ACC (pACC/ACC) was increased in gastrocnemius skeletal muscle of mice receiving GLP-1(32-36)amide for 16 weeks and on HFD for 24 weeks when compared with vehicle-treated mice (Fig. 5D and E). No changes were observed in skeletal muscle for UCP-3 protein (Fig. 5D), although UCP-3 mRNA was increased (Fig. 5F). Muscles of GLP-1(32-36)amide–treated mice showed either no change or a moderate increase in the transcription of genes associated with oxidative metabolism and/or mitochondrial biogenesis, such as PGC-1α, PPARα/γ, COX4i1, and COX7a1 (Fig. 5F). The expression of SCD-1 however was substantially decreased, suggesting a decrease in muscle adiposity, possibly due to an increase in fatty acid metabolism (Fig. 5F). Increased fatty acid oxidation in skeletal muscle might provide the fuel required to fulfill the energetic demands imposed by the increased energy expenditure in mice treated with the pentapeptide.
Similar findings of increased muscle oxidative phosphorylation were observed in C2C12 myotubes. The incubation of myotubes with GLP-1(32-36)amide (100 pmol/L) for 16 h increased both the ratio between phosphorylation of AMPK and the total expression of AMPK (pAMPK/AMPK) and the phosphorylation (inhibitory) of its downstream target ACC without differences in the expression of total ACC (Fig. 6A–C). Likewise, GLP-1(32-36)amide restored the decreased phosphorylation of both AMPK and ACC phosphorylation in C2C12 myotubes in which oxidative metabolism had been impaired by pretreatment of the myotubes with palmitate for 16 h (Fig. 6C and D). In addition, GLP-1(32-36)amide reduces intracellular levels of ROS induced in C2C12 myotubes by their treatment with palmitate (Fig. 6E).
Herein we describe the identification and the partial characterization of the actions of a pentapeptide, GLP-1(32-36)amide (LVKGRamide), derived from the C terminus of the glucoregulatory hormone GLP-1. The pentapeptide appears to arise in the circulation via the cleavage of GLP-1 by an endopeptidase such as neprilysin (NEP 24.11) (9) or a related endopeptidase. Mass spectrometry detected the appearance of the pentapeptide in plasma after the intraperitoneal injection of GLP-1(9-36)amide in mice. The pentapeptide was postulated to exist in vivo based on the evidence that neprilysin generates the pentapeptide from GLP-1 (9), and a candoxatril-sensitive endopeptidase decreases levels of infused GLP-1 in the circulation of pigs (34).
The pentapeptide is biologically active when infused into DIO mice and when added to cultured C2C12 myotubes. Pentapeptide infusions in DIO mice increase basal energy expenditure without effect on energy intake and inhibit weight gain and the development of insulin resistance and hepatic steatosis. Several observations indicate that increased energy expenditure is a major action of the pentapeptide. Pentapeptide-treated mice showed a 20–30% increase in oxygen consumption without significant changes in physical activity or food intake. Food intake was no different among vehicle control and treated groups. The FE showed that ~80% less of the caloric intake went into body weight in mice infused with the pentapeptide compared with vehicle control mice, indicating the existence of a substantial dissipation of the intake of caloric energy in pentapeptide-treated mice. Furthermore the pentapeptide increases the expression of the uncoupling proteins UCP-1 and UCP-3 in BAT and decreases the activity of ACC in skeletal muscle of mice, indicative of increased fatty acid oxidation (35,36). The physiological mechanisms of GLP-1(32-36)amide on the inhibition of weight gain differ from those of GLP-1 receptor agonists. Receptor agonists inhibit energy intake with little or no effects on energy expenditure (37–40). Notably, basal energy expenditure is increased in mice lacking the GLP-1 receptor (41), suggesting a lowering of energy expenditure in response to receptor activation.
Although the precise mechanisms by which GLP-1(32-36)amide promotes energy expenditure remain unknown, one mechanism might be the uncoupling of mitochondrial respiration. Uncoupling dissipates energy in the form of heat (thermogenesis) and reduces mitochondrial energy overload and membrane charge and the formation of ROS (oxidative stress) (42). The findings of increased UCP-1 and UCP-3 expression in BAT and UCP-3 expression in skeletal muscle of mice treated with GLP-1(32-36)amide are consistent with an uncoupling of respiration. We suggest that the activation UCPs in BAT, and the resulting increased energy dissipation, contributes to the metabolic phenotype observed in the pentapeptide-treated mice. The transplantation of BAT tissue into either normal or DIO mice improves glucose tolerance, increases insulin sensitivity, and lowers body weight and fat mass (43).
A notable finding was the normalization of the hepatic triglyceride content in obese mice infused with the pentapeptide to levels found in lean mice fed a normal chow diet. This finding suggests that the peptide prevented, or possibly reversed, the development of hepatic steatosis. Although we did not measure triglyceride levels in the livers of the obese mice prior to starting the infusions of the pentapeptide, it is likely that the mice had fatty livers after 17 weeks on the HFD, the time that the infusions began. Male C57BL/6 mice characteristically develop simple hepatic steatosis and elevated levels of liver triglycerides by at least 12 weeks on the HFD (60 kcal fat) used in our studies (18).
In studies of cultured C2C12 skeletal myotubes, the pentapeptide activates the energy sensor AMPK, inhibits ACC, and prevents an increase in levels of ROS in response to palmitate treatment. AMPK phosphorylates and inhibits ACC. ACC regulates the anabolism and catabolism of fatty acids via the formation of malonyl-CoA, both a substrate for the synthesis of fatty acids and an inhibitor of fatty acid oxidation. Inhibition of ACC reduces malonyl-CoA levels and relieves inhibition of carnitine palmitoyl transferase-1, required for the transport and oxidation of fatty acids in mitochondria. AMPK-mediated inhibition of ACC activity by the pentapeptide and enhanced fatty acid oxidation might account for the reduction in body fat mass observed in response to the pentapeptide.
The pentapeptide increased the transcriptional expression of UCP-3 in C2C12 myotubes and the skeletal muscle. Although the role of UCP-3 in skeletal muscle is controversial (44), it is believed that UCP-3 serves as a fatty acid transporter (29,30). The transport of fatty acids from the mitochondrial matrix to the outside of the inner membrane captures protons that are then carried retrograde back through the membrane to the matrix, thereby causing a proton leakage and energy dissipation (30,43).
We speculate that the de novo lipogenesis pathway might be modulated by GLP-1(32-36)amide. The findings of increased basal energy expenditure, activation of AMPK, and increased fatty acid oxidation in pentapeptide-treated obese mice, coupled with an enhanced glucose disposal in hyperglycemic dogs in response (45), raises the possibility that GLP-1(32-36)amide might act via AMPK-responsive pathways similar to those activated by leptin that induce de novo lipogenesis in skeletal muscle (35). De novo lipogenesis would explain the findings of the effects of GLP-1(32-36)amide on BAT and skeletal muscle as de novo lipogenesis, mediated by AMPK, links glucose uptake and fatty acid synthesis and oxidation with futile substrate cycling and facultative thermogenesis (31).
In summary, the findings described here suggest that GLP-1(32-36)amide might be an effective treatment for obesity and its related metabolic disorders in humans. In mice, the pentapeptide appears to modulate mitochondrial energy metabolism by increasing energy expenditure and fat metabolism, resulting in a reduction in rates of weight gain, body fat mass, oxidative stress, and insulin resistance. The pentapeptide is a product of the GLP-1 hormone naturally produced in the body. No adverse effects were observed in mice receiving continuous infusion of the pentapeptide for up to 16 weeks, suggesting that the pentapeptide might have a favorable safety profile, as well as efficacy in curtailing weight gain and possibly even promoting weight loss in humans. Whether or not the pentapeptide is active in humans, as well as in mice and dogs, awaits the results of clinical trials.
Funding. This study was supported in part by a National Institutes of Health P30 Diabetes Endocrinology Research Center grant (DK-057521).
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. E.T. conceived of and performed the experiments, evaluated data, and prepared the figures and the manuscript. V.S. and K.M. participated in the experimental work and in the analysis of the data. A.K. synthesized, purified, and characterized the pentapeptide. P.E. and W.W.B. conducted and planned the mass spectroscopy experiments. J.F.H. conceived of experiments, evaluated data, and contributed to the manuscript. J.F.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Prior Presentation. Parts of this study were presented in abstract form at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, PA, 8–12 June 2012; the 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, 21–25 June 2013; and the 74th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 13–17 June 2014.
E.T. is currently affiliated with the Cardiovascular and Metabolic Diseases Research Unit, Pfizer Research Technology Center, Cambridge, MA.